How did Bright Minds' operating profit turn positive in Q3 2024?

Bright Minds Biosciences reported a positive operating cash flow of €2.7 million over the last 12 months as of June 30, 2024, which reflects the company's ability to generate cash in a difficult market environment. The company's net loss reduced significantly from €5.8 million in Q3 2023 to €1.8 million in Q3 2024, and the company maintained a cash balance of €6.2 million as of June 30, 2024. These improvements indicate that Bright Minds' operating profit turned positive in Q3 2024 due to enhanced financial management and reduced net losses, despite not reporting any revenue for the quarter.